Hoban D, Grabowski M, Koss J, Weselowski V
Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, Manitoba, Canada.
Diagn Microbiol Infect Dis. 1989 May-Jun;12(3 Suppl):77S-82S. doi: 10.1016/0732-8893(89)90070-9.
The in vitro activity of lomefloxacin, a new difluoro-quinolone, was compared to other antimicrobial agents against a selection of Gram-positive and Gram-negative organisms. Against the Enterobacteriaceae, the lomefloxacin MIC inhibiting 90% of strains was less than or equal to 0.5 micrograms/ml. Ninety per cent of Pseudomonas aeruginosa and Acinetobacter sp. isolates were inhibited at less than or equal to 4 micrograms/ml. All staphylococci including methicillin-resistant organisms were susceptible at 1.0 micrograms/ml. Enterococcus faecalis, Listeria spp., and sero Group B streptococci were more resistant with an MIC90 of 8, 16 and 4 micrograms/ml, respectively.
将新型二氟喹诺酮类药物洛美沙星的体外活性与其他抗菌药物针对一系列革兰氏阳性和革兰氏阴性菌的活性进行了比较。对于肠杆菌科细菌,抑制90%菌株的洛美沙星MIC小于或等于0.5微克/毫升。90%的铜绿假单胞菌和不动杆菌属分离株在小于或等于4微克/毫升时受到抑制。包括耐甲氧西林菌株在内的所有葡萄球菌在1.0微克/毫升时均敏感。粪肠球菌、李斯特菌属和B族血清型链球菌的耐药性更强,MIC90分别为8、16和4微克/毫升。